[{"id":"ec39bba5-c725-4310-a7b9-db843f8fcd99","acronym":"AdvanTIG-206","url":"https://clinicaltrials.gov/study/NCT04948697","created_at":"2021-07-02T12:52:38.466Z","updated_at":"2025-02-25T12:28:13.406Z","phase":"Phase 2","brief_title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","source_id_and_acronym":"NCT04948697 - AdvanTIG-206","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2025-02-24"},{"id":"b338379e-ef5a-43a2-a2ae-225d86a98ac0","acronym":"AdvanTIG-203","url":"https://clinicaltrials.gov/study/NCT04732494","created_at":"2021-02-01T16:58:08.345Z","updated_at":"2025-02-25T17:30:34.219Z","phase":"Phase 2","brief_title":"Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT04732494 - AdvanTIG-203","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/26/2023","study_completion_date":" 12/26/2023","last_update_posted":"2025-01-31"},{"id":"ea707ec7-5a15-4d00-85aa-eb195dfbadbf","acronym":"BGB-LC-202","url":"https://clinicaltrials.gov/study/NCT05577702","created_at":"2022-10-13T17:58:07.280Z","updated_at":"2025-02-25T16:18:14.799Z","phase":"Phase 2","brief_title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05577702 - BGB-LC-202","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-18"},{"id":"741a0fc0-531f-4a17-bbe4-9bce8f823ccb","acronym":"AdvanTIG-302","url":"https://clinicaltrials.gov/study/NCT04746924","created_at":"2021-02-10T15:55:05.413Z","updated_at":"2024-07-02T16:34:59.848Z","phase":"Phase 3","brief_title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","source_id_and_acronym":"NCT04746924 - AdvanTIG-302","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 662","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-31"},{"id":"7a0c7254-8e87-4d9f-b984-e531b63a99e9","acronym":"AdvanTIG-205","url":"https://clinicaltrials.gov/study/NCT05014815","created_at":"2021-08-20T14:53:03.113Z","updated_at":"2024-07-02T16:35:02.504Z","phase":"Phase 2","brief_title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05014815 - AdvanTIG-205","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"dc7aba31-8ae9-4dea-b47e-ae95be0bd48a","acronym":"AdvanTIG-105","url":"https://clinicaltrials.gov/study/NCT04047862","created_at":"2021-01-18T19:51:12.563Z","updated_at":"2024-07-02T16:35:16.919Z","phase":"Phase 1","brief_title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT04047862 - AdvanTIG-105","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 449","initiation":"Initiation: 08/26/2019","start_date":" 08/26/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-03-01"},{"id":"c185a188-d064-4853-9238-aff104f6cc65","acronym":"","url":"https://clinicaltrials.gov/study/NCT05267054","created_at":"2022-03-04T15:53:29.958Z","updated_at":"2024-07-02T16:35:29.571Z","phase":"Phase 1/2","brief_title":"Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab","source_id_and_acronym":"NCT05267054","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-11-10"},{"id":"68568d37-21f2-4b3b-a994-81af7518adda","acronym":"AdvanTIG-202","url":"https://clinicaltrials.gov/study/NCT04693234","created_at":"2021-01-19T20:49:03.675Z","updated_at":"2024-07-02T16:35:31.388Z","phase":"Phase 2","brief_title":"AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT04693234 - AdvanTIG-202","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • mipsagargin (G-202)"],"overall_status":"Completed","enrollment":" Enrollment 178","initiation":"Initiation: 02/15/2021","start_date":" 02/15/2021","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-10-27"},{"id":"a4ff347e-38b5-467c-999e-232ce807ec47","acronym":"AdvanTIG-211","url":"https://clinicaltrials.gov/study/NCT05809895","created_at":"2023-04-12T14:03:22.585Z","updated_at":"2024-07-02T16:35:42.162Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT05809895 - AdvanTIG-211","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 07/17/2029","primary_completion_date":" 07/17/2029","study_txt":" Completion: 07/18/2029","study_completion_date":" 07/18/2029","last_update_posted":"2023-07-24"},{"id":"aff5284c-d7d1-4bbb-a3af-3ff26aeca690","acronym":"AdvanTIG-306","url":"https://clinicaltrials.gov/study/NCT05791097","created_at":"2023-03-30T14:03:23.736Z","updated_at":"2024-07-02T16:35:42.225Z","phase":"Phase 3","brief_title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","source_id_and_acronym":"NCT05791097 - AdvanTIG-306","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 12/24/2027","primary_completion_date":" 12/24/2027","study_txt":" Completion: 12/26/2027","study_completion_date":" 12/26/2027","last_update_posted":"2023-07-24"}]